Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Global, Multicenter, Long-term Safety Study Designed to Assess the Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy

NCT06443463 is registered in ClinicalTrials.gov with Biohaven Therapeutics Ltd. as lead sponsor.

NCT NCT06443463
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06443463 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Global, Multicenter, Long-term Safety Study Designed to Assess the Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy
Lead sponsor
Biohaven Therapeutics Ltd.
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
July 30, 2024
Completion date
January 31, 2027
Enrollment
660 (estimated)
Sites
283

Conditions

As the registry lists them; a condition with its own page is linked.

focal epilepsy